The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.

Britain's top brass filed into my office in No 10, bearing with them hundreds of years of collective operational experience, ...

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...

Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...

The vaccine race: it was Brexit and Bingham what won it. There were good reasons for any member of the Tory Government to ...

While there are a few different strategies to build wealth through the stock market, this Footsie ETF may be the most ...